Edition:
United States

Swedish Orphan Biovitrum AB (publ) (SOBIV.ST)

SOBIV.ST on Stockholm Stock Exchange

112.10SEK
15 Dec 2017
Change (% chg)

-0.10kr (-0.09%)
Prev Close
112.20kr
Open
111.70kr
Day's High
112.10kr
Day's Low
110.00kr
Volume
1,494,505
Avg. Vol
615,242
52-wk High
143.80kr
52-wk Low
101.60kr

Chart for

About

Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers... (more)

Overall

Beta: 1.63
Market Cap(Mil.): kr30,548.11
Shares Outstanding(Mil.): 272.51
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.20 16.04
EPS (TTM): -- -- --
ROI: -- 15.06 34.69
ROE: -- 16.55 15.46

UPDATE 1-Sobi to scale up in North America as Q3 beats expectations

Oct 25 Rare-disease drug maker Swedish Orphan Biovitrum (Sobi) reported on Wednesday a bigger jump than expected in quarterly core profit, raised its profit and sales guidance, and said it planned to boost operations in North America.

Oct 25 2017

BRIEF-Swedish Orphan Biovitrum says Alprolix approved for use in Saudi Arabia‍​

* Alprolix approved for treatment of Hemofili B in Saudi Arabia.‍​ Source text for Eikon: Further company coverage: (Reporting By Johan Sennero)

Oct 25 2017

BRIEF-Sobi raises outlook as Q3 core profit beats expectations

* Swedish orphan biovitrum says ‍sobi now expects total revenues for full year to be in range of sek 6,300 to 6,400 m (6,100-6,200)​

Oct 25 2017

BRIEF-Sobi Q2 EBITA falls, raises 2017 guidance

* Swedish orphan biovitrum Q2 total revenue was SEK 1,639 mln (1,469)

Jul 19 2017

Earnings vs. Estimates